Real-world First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: the Multicenter ASTRUM-005R Study.

L. Wu,C. Hu, W. Su,Y. Yu,W. Hong,Z. Liu,H. Su, C. Wang, Q. Pu,H. Guo, X. Min, Y. Chen, H. Zhu, T. Luo

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited 0|Views1

Key words

Extensive-stage small cell lung cancer,PD-1 inhibitor,Serplulimab

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined